[E-Daily Reporter Kim Jinsoo ] Voronoi, Inc.(310210)’s new anticancer drug candidate “VRN10” (VRN101099) demonstrated early antitumor activity by achieving a partial response (PR) in patients with HER2-mutated solid tumors. However, based solely on the data disclosed by Voronoi, Inc., it is difficult to assess the balance between efficacy and safety across different dosage levels, suggesting that further analysis is needed.
Although Voronoi, Inc.’s investor relations (IR) materials also confirmed PR at multiple doses, they did not present comprehensive results combining the number of patients evaluated and the number of responders by dose. Safety data was also presented as an aggregate of all patients receiving various doses. Consequently, further evaluation appears necessary to determine how much the therapeutic effect improves when the dose is increased and how the burden of side effects changes.
A poster of the VRN10 clinical trial released by Voronoi, Inc. (Photo courtesy of Voronoi, Inc.) According to the Phase 1 clinical trial poster presented by Voronoi, Inc. last month at the European Society for Medical Oncology (ESMO) Congress, 12 out of 16 HER2-mutant patients underwent at least one tumor assessment. Among patients with HER2 tyrosine kinase domain (TKD) mutations, 2 out of 5 showed a partial response (PR), while among those with mutations in other regions (non-TKD), 3 out of 7 showed a PR. The objective response rates (ORR) were 40% and approximately 43%, respectively.
These results are significant in that antitumor activity was observed across different HER2 mutations. However, since the specific number of patients evaluated at each dose level and the number of responders were not provided, there are limitations to evaluating the actual therapeutic efficacy at each dose level.
Generally, in a Phase 1a trial, a new drug candidate is administered to humans for the first time to evaluate safety, tolerability, and pharmacokinetics. For anticancer drugs, dose escalation—a process of gradually increasing the dose—is used to identify dose-limiting toxicities (DLTs) and the maximum tolerated dose (MTD).
The reason for verifying efficacy by dose is that a drug’s therapeutic effect does not always correlate with the dose administered. Antitumor activity may improve up to a certain dose, but beyond a specific level, additional benefits may be limited. Conversely, at lower doses, it may not be possible to achieve sufficient drug exposure.
Therefore, analyzing both the response rate and drug exposure at each dose is necessary to accurately identify the dose at which a meaningful therapeutic effect is observed. In particular, since Phase 1 clinical trials are designed to evaluate safety at different doses and identify an appropriate dose for subsequent trials, it is crucial to determine what tumor responses and adverse effects occurred at each dose.
Correlation Between Drug Exposure and Tumor Reduction… Benefits of Dose Escalation Require Further Validation
According to data released by Voronoi, Inc., in patients with TKD-mutated lung cancer harboring the YVMA insertion mutation, the sum of lung target lesion sizes decreased by 56.1% at a 240 mg dose of VRN10, while in patients with the L755P mutation, it decreased by 35.8% at a 320 mg dose. In non-TKD settings, patients with S310Y-mutated lung cancer showed a partial response (PR) at 160 mg, and patients with V659E-mutated renal cell carcinoma showed a PR at 320 mg. However, given differences in conditions such as mutation types, it is difficult to interpret these results as differences in efficacy based on dose.
Determining the dose-dependent effect is directly linked to selecting the recommended dose. For example, if sufficient efficacy is already achieved at 240 mg and there is no additional benefit at 480 mg, there is no reason to choose a higher dose and risk side effects. However, based solely on the data currently released by Voronoi, Inc., it is difficult to determine which option is more advantageous.
The safety assessment analyzed 50 patients who received at least one dose ranging from 80 to 480 mg. Treatment-related adverse events occurred in 38 patients (76%), with Grade 3 or higher events observed in 3 patients (6%). Diarrhea, the most common adverse event, occurred in 26 patients (52%), of whom 2 experienced Grade 3 or higher events. Since this is an analysis of the entire dose range, it is not possible to assess safety by specific dose.
Dose-specific adverse event data is crucial for determining the dose at which patients can actually continue treatment. This is because even if tumor suppression improves at higher doses, repeated treatment interruptions or dose reductions due to side effects can reduce the actual therapeutic benefit.
Since VRN10 has not yet reached its maximum tolerated dose (MTD), the recommended Phase 2 dose (RP2D) has not been determined. The RP2D serves as the criterion for determining the dose to be administered to a large number of patients in subsequent clinical trials. Selecting a dose with insufficient efficacy may fail to sufficiently demonstrate the drug’s therapeutic potential, while selecting a dose that is unnecessarily high may affect clinical outcomes due to an increase in adverse events and treatment discontinuations.
Since a 560 mg dose of VRN10 is currently being administered, further analysis of dose-specific efficacy and safety data will likely be required.
Voronoi, Inc. plans to review dosages for monotherapy in HER2-activating mutation-positive non-small cell lung cancer and combination therapy in HER2-positive solid tumors, with the goal of initiating a Phase 1b trial in early 2027.
In this regard, PharmDaily inquired with Voronoi, Inc. regarding whether additional data analysis related to this clinical trial would be conducted, but Voronoi, Inc. did not provide a separate response.
Tension is mounting in the domestic credit market after the U.S. Federal Reserve (Fed) raised its benchmark interest rate last September for the first time in about three years. As inflationary pressu…
Voronoi, Inc.(310210)’s new anticancer drug candidate “VRN10” (VRN101099) demonstrated early antitumor activity by achieving a partial response (PR) in patients with HER2-mutated solid tumors. However…
Rainbow Robotics(277810)reported a widening net loss in the third quarter of this year despite revenue growth. While sales to its largest shareholder, SamsungElectronics, increased, the proportion of …